Advertisement

2017 Multidisciplinary Thoracic Cancers Symposium

lung cancer

Douglas E. Wood, MD, on Lung Cancer Screening

Douglas E. Wood, MD, of the University of Washington, discusses the importance of broad access to and education about lung cancer screening—now approved for people at high risk for the disease—and the...

lung cancer

Charles B. Simone, II, MD, on NSCLC: CTCs as a Biomarker for Early Detection

Charles B. Simone, II, MD, of the University of Maryland Medical Center, discusses results from a large prospective study in locally advanced non–small cell lung cancer, which suggest that circulating...

lung cancer

Boris Sepesi, MD, on NSCLC, TILs, and Overall Survival

Boris Sepesi, MD, of The University of Texas MD Anderson Cancer Center, discusses immune cells within tumors and the potential role for checkpoint inhibitor therapy in the neoadjuvant setting of local...

lung cancer

Zofia Piotrowska, MD, on NSCLC: Resistance Mechanisms

Zofia Piotrowska, MD, of the Massachusetts General Hospital Cancer Center, discusses heterogeneity and variation in resistance mechanisms among EGFR-mutant non–small cell lung cancer patients with at ...

lung cancer

Zhongxing Liao, MD, on Proton-Beam Radiotherapy for Locally Advanced Disease

Zhongxing Liao, MD, of The University of Texas MD Anderson Cancer Center, discusses the continued improvement in planning, delivery, and patient selection for proton therapy, which can both reduce rad...

lung cancer

Jennifer Ho, MD, on Thoracic Cancers: Reirradiation With IMPT

Jennifer Ho, MD, of The University of Texas MD Anderson Cancer, discusses study results on the use of intensity-modulated proton therapy, which can provide durable local control with minimal toxicity ...

lung cancer

Tracey L. Evans, MD, on NSCLC: Combined-Modality Therapy

Tracey L. Evans, MD, of the University of Pennsylvania, discusses the data supporting use of chemotherapy with radiation in locally advanced non–small cell lung cancer, targeted treatments and immunot...

lung cancer

Martin J. Edelman, MD, on NSCLC: Final Results of a CALGB Alliance Trial

Martin J. Edelman, MD, of Fox Chase Cancer Center, discusses study findings from a phase III study of celecoxib in addition to standard chemotherapy for advanced non–small cell lung cancer with COX-2 ...

lung cancer

Maximilian Diehn, MD, PhD, on Liquid Biopsies/Cell-Free DNA: Clinical Uses

Maximilian Diehn, MD, PhD, of Stanford School of Medicine, discusses promising clinical applications of circulating tumor DNA in patients with thoracic malignancies: noninvasive detection of resistanc...

lung cancer

Shraddha M. Dalwadi, MBA, on Stage I NSCLC: Racial Disparities in Treatment and Outcome

Shraddha M. Dalwadi, MBA, MD Candidate in the class of 2017 at Texas A&M Health Science Center, discusses findings from a SEER database study that showed African Americans and American Indians wit...

lung cancer

Richard J. Cassidy III, MD, on NSCLC and SBRT in Older Patients

Richard J. Cassidy III, MD, of Emory Winship Cancer Institute, discusses results from a multicenter analysis of stereotactic body radiotherapy for early-stage non-small cell lung cancer in patients 80...

lung cancer

Kamran Ahmed, MD, on Lung Cancer, Radiation, and Immune Checkpoint Inhibitors

Kamran Ahmed, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses results from a small study of pneumonitis in patients who received thoracic radiotherapy within 6 months of anti...

Advertisement

Advertisement



Advertisement

click me